Mangoceuticals Clears Path for Up to $10M Series D Preferred Offering
MGRX sits 17% above its 52-week low of $0.162 on light trading volume (0.2× avg).
Summary
Mangoceuticals' sole Series B preferred holder approved a new 8% Series D convertible preferred, clearing the way for a Regulation A offering of up to 1,000,000 shares at $10.00 each, or up to $10,000,000. The designation is not yet filed or effective, and the company may not proceed.
Key Events · Financing and Capital Events · MGRX
-
Series D Preferred Approved by Sole B Holder
On November 2, 2026, the holder of all 50 Series B preferred shares consented in writing to the Series D designation and to a Series B amendment that subordinates existing dividend and liquidation rights.
-
Up to $10M Regulation A Offering Contemplated
Under Regulation A, the company may sell up to 1,000,000 Series D shares at $10.00 per share, or up to $10,000,000, in one or more transactions.
-
Nothing Filed or Effective Yet
Neither the Series B Amendment nor the Series D Designation has been filed with the Texas Secretary of State; no sales can occur before the SEC qualifies a Form 1-A offering statement, and the company may abandon the offering.
-
Combined Annual Meeting Set for December 30
The combined 2025 and 2026 annual meeting will be held December 30, 2026, with a November 12, 2026 record date and a November 16, 2026 deadline for shareholder proposals and director nominations.
Analysis · MGRX · Industrial Applications And Services
A single holder of all 50 Series B preferred shares has signed off on a new 8% Series D convertible preferred that would rank ahead of the existing Series B on dividends and liquidation. Through a Regulation A offering, the company is authorized to sell up to 1,000,000 Series D shares at $10.00 each, or up to $10,000,000 — roughly 23x the company's current market value, making the raise transformative if completed. Nothing is effective yet: the designation has not been filed with Texas, no Form 1-A has been qualified, and management can walk away. For a company that previously disclosed a going-concern warning and Nasdaq delisting risk, this is the latest in a string of small raises and asset sales, and the senior ranking means common holders sit further back in the capital stack.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.16 to $2.41. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.